Valneva Aktie

3,65 EUR ±0,00 EUR +0,11 %

23.12.2025

BMN

3,85 EUR -0,22 EUR -5,31 %

03.11.2025

LSE

Valneva jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.632,60 Mio. EUR

Div. Rendite0,00%

WKNA0MVJZ

ISINFR0004056851

SymbolINRLF

Valneva Aktien News

Sortieren:Datum Meistgelesen

20.03.24GlobeNewswireValneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

18.03.24GlobeNewswireValneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

06.03.24GlobeNewswireVALNEVA Declaration of shares and voting rights - February 29, 2024

04.03.24GlobeNewswireValneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

29.02.24GlobeNewswireU.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

15.02.24GlobeNewswireValneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

07.02.24GlobeNewswireVALNEVA: Declaration of shares and voting rights - January 31, 2024

05.02.24GlobeNewswireValneva Announces Sale of Priority Review Voucher for $103 Million

10.01.24GlobeNewswireValneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

05.01.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: December 31, 2023

04.01.24GlobeNewswireValneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

29.12.23GlobeNewswireValneva Provides Updated 2023 Financial Guidance

20.12.23GlobeNewswireValneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

06.12.23GlobeNewswireVALNEVA Declaration of shares and voting rights - November 30, 2023

04.12.23GlobeNewswirePfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

04.12.23GlobeNewswireValneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

27.11.23GlobeNewswireEMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

15.11.23GlobeNewswireValneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

13.11.23GlobeNewswireValneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

10.11.23GlobeNewswireValneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

09.11.23GlobeNewswireValneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

07.11.23GlobeNewswireValneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

06.11.23GlobeNewswireVALNEVA Declaration of shares and voting rights: October 31, 2023

25.10.23GlobeNewswireValneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

11.10.23GlobeNewswireValneva to Present on Chikungunya at Several Leading Scientific Conferences

05.10.23GlobeNewswireVALNEVA - Declaration of shares and voting rights: September 30, 2023

25.09.23GlobeNewswireValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

21.09.23GlobeNewswireValneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

07.09.23GlobeNewswireValneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

06.09.23GlobeNewswireVALNEVA Declaration of shares and voting rights: August 31, 2023

31.08.23GlobeNewswireValneva to Participate in Investor Conferences in the United States and Europe in September 2023

29.08.23GlobeNewswireHealth Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

28.08.23GlobeNewswireValneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

17.08.23GlobeNewswireValneva Announces Extension of Existing Loan Agreement

14.08.23GlobeNewswireValneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

03.08.23GlobeNewswireVALNEVA Declaration of shares and voting rights - July 31, 2023

05.07.23GlobeNewswireVALNEVA - Declaration of shares and voting rights: June 30, 2023

22.06.23GlobeNewswireValneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors

21.06.23GlobeNewswire Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board

13.06.23GlobeNewswireValneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet

Valneva News

Valneva News: auf dieser Seite finden Sie alle Valneva News und Nachrichten zur Valneva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Valneva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Valneva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.